Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mPGES-1 inhibitor agent
- Development stage
- Unknown
- Lead developer
- ASKA Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The mPGES-1 inhibitor agent is a small molecule therapeutic candidate currently under development by ASKA Pharmaceutical. It specifically targets microsomal prostaglandin E synthase-1 (mPGES-1), an enzyme that acts downstream of cyclooxygenase-2 (COX-2) to catalyze the conversion of prostaglandin H2 (PGH2) into prostaglandin E2 (PGE2). PGE2 is a key lipid mediator involved in the pathogenesis of pain and inflammation. By selectively inhibiting mPGES-1, this agent aims to reduce PGE2 levels while sparing other prostanoids, such as prostacyclin (PGI2), which are often suppressed by traditional non-steroidal anti-inflammatory drugs (NSAIDs) and COX-2 inhibitors. This selective mechanism is intended to provide potent anti-inflammatory and analgesic effects with a potentially improved safety profile, particularly regarding gastrointestinal and cardiovascular side effects. The drug is currently in Phase 1 clinical development.
- Other names
- ASKA Pharmaceutical-mPGES-1-small moleculemPGES-1-small moleculemPGES1-small moleculemPGES 1-small molecule
02
Targets
PTGES (Microsomal prostaglandin E synthase-1)
Beyond the preview
Go deeper on mPGES-1 inhibitor agent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mPGES-1 inhibitor agent.